Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Next Previous
Trial Profile

An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Angle-closure glaucoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eyenovia

    • Most Recent Events

    • 28 Nov 2018 Results presented in an Eyenovia media release.
    • 28 Nov 2018 According to an Eyenovia media release, results from this study were published in the November 2018 issue of the peer-review journal Clinical Ophthalmology.
    • 13 Nov 2018 According to an Eyenovia media release, data from the study have been accepted for publication by the peer-reviewed journal Clinical Ophthalmology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top